studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), pembrolizumab plus ipilimumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-598, 2020 1.08 [0.85; 1.37] 1.08[0.85; 1.37]KEYNOTE-598, 202010%568NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-598, 2020 1.06 [0.86; 1.30] 1.06[0.86; 1.30]KEYNOTE-598, 202010%568NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-598, 2020 1.00 [0.72; 1.39] 1.00[0.72; 1.39]KEYNOTE-598, 202010%568NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.14 [0.41; 3.20] 1.14[0.41; 3.20]KEYNOTE-598, 202010%563NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.01 [0.36; 11.05] 2.01[0.36; 11.05]KEYNOTE-598, 202010%563NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.25 [0.03; 2.22] 0.25[0.03; 2.22]KEYNOTE-598, 202010%563NAnot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.00 [0.14; 7.12] 1.00[0.14; 7.12]KEYNOTE-598, 202010%563NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.02; 14.89] 0.50[0.02; 14.89]KEYNOTE-598, 202010%563NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 6.03 [0.30; 120.98] 6.03[0.30; 120.98]KEYNOTE-598, 202010%563NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 10.29 [1.31; 80.96] 10.29[1.31; 80.96]KEYNOTE-598, 202010%563NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.87 [0.31; 2.43] 0.87[0.31; 2.43]KEYNOTE-598, 202010%563NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.51 [0.42; 5.39] 1.51[0.42; 5.39]KEYNOTE-598, 202010%563NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.00 [0.06; 16.01] 1.00[0.06; 16.01]KEYNOTE-598, 202010%563NAnot evaluable Increase AST AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.52 [0.48; 13.09] 2.52[0.48; 13.09]KEYNOTE-598, 202010%563NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.28 [0.69; 7.50] 2.28[0.69; 7.50]KEYNOTE-598, 202010%563NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 4.01 [0.18; 89.26] 4.01[0.18; 89.26]KEYNOTE-598, 202010%563NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.36 [0.72; 2.56] 1.36[0.72; 2.56]KEYNOTE-598, 202010%563NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.21 [0.83; 5.91] 2.21[0.83; 5.91]KEYNOTE-598, 202010%563NAnot evaluable Pruritus AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 6.03 [0.30; 120.98] 6.03[0.30; 120.98]KEYNOTE-598, 202010%563NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 16.38 [0.94; 286.59] 16.38[0.94; 286.59]KEYNOTE-598, 202010%563NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 4.03 [0.45; 36.27] 4.03[0.45; 36.27]KEYNOTE-598, 202010%563NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:40 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 769